Asmaa F. Kassem

Dr. Asmaa F. Kassem


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Journal of Molecular Structure
Verified
Journal Article
Closed access
AKAsmaa F. Kassem
Asmaa F. Kassem
RARaed H. Althomali
Raed H. Althomali
MAManal M. Anwar
Manal M. Anwar
WEWalaa I. El-Sofany
Walaa I. El-Sofany

22 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
WEWael A. El-Sayed
Wael A. El-Sayed
FAFahad Alminderej
Fahad Alminderej
MMMarwa Mounier
Marwa Mounier
ENEman Nossier
Eman Nossier
Sayed M. SalehSayed M. Saleh
Sayed M. Saleh
AKAsmaa F. Kassem
Asmaa F. Kassem
This study represents the design and synthesis of a new set of triazole-coumarin-glycosyl hybrids and their tetrazole hybrid analogues possessing various sugar moieties and modified analogues. All the newly synthesized derivatives were screened for their cytotoxic activities against a panel of human cancer cell lines. The coumarin derivatives 10, 13 and 15 derivatives revealed potent cytotoxic activities against Paca-2, Mel-501, PC-3 and A-375 cancer cell lines. These promising analogues were further examined for their inhibitory assessment against EGFR, VEGFR-2 and CDK-2/cyclin A2 kinases. The coumarin-tetrazole 10 displayed broad superior inhibitory activity against all screened enzymes compared with the reference drugs, erlotinib, sorafenib and roscovitine, respectively. The impact of coumarin-tetrazole 10 upon cell cycle and apoptosis induction was determined to detect its mechanism of action. Additionally, it upregulated the levels of casp-3, casp-7 and cytochrome-c proteins and downregulated the PD-1 level. Finally, molecular docking study was simulated to afford better rationalization and gain insight into the binding affinity between the promising derivatives and their targeted enzymes, which could be used as an optimum lead for further modification in the anticancer field.

6 February 2024 in European Polymer Journal
Verified
Journal Article
Closed access
SHAHID KHANSHAHID KHAN
SHAHID KHAN
MUMuneeb Ullah
Muneeb Ullah
SSSumbul Saeed
Sumbul Saeed
SASuaad Ahmed Saeed Hassen Aga
Suaad Ahmed Saeed Hassen Aga
AKAsmaa F. Kassem
Asmaa F. Kassem
Kun LuKun Lu
Kun Lu


3 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
WEWael A. El-Sayed
Wael A. El-Sayed
FAFahad Alminderej
Fahad Alminderej
MMMarwa Mounier
Marwa Mounier
ENEman Nossier
Eman Nossier
Sayed M. SalehSayed M. Saleh
Sayed M. Saleh
AKAsmaa F. Kassem
Asmaa F. Kassem
Toxicity and resistance to newly synthesized anticancer drugs represent a challenging phenomenon of intensified concern arising from variation in drug targets and consequently the prevalence of the latter concern requires further research. The current research reports the design, synthesis, and anticancer activity of new 1,2,3-triazole-coumarin-glycosyl hybrids and their 1,2,4-triazole thioglycosides as well as acyclic analogs. The cytotoxic activity of the synthesized products was studied against a panel of human cancer cell lines. Compounds 8, 10, 16 and 21 resulted in higher activities against different human cancer cells. The impact of the hybrid derivative 10 upon different apoptotic protein markers, including cytochrome c, Bcl-2, Bax, and caspase-7 along with its effect on the cell cycle was investigated. It revealed a mitochondria-apoptotic effect on MCF-7 cells and had the ability to upregulate pro-apoptotic Bax protein and downregulate anti-apoptotic Bcl-2 protein and thus implies the apoptotic fate of the cells. Furthermore, the inhibitory activities against EGFR, VEGFR-2 and CDK-2/cyclin A2 kinases for 8, 10 and 21 were studied to detect the mechanism of their high potency. The coumarin-triazole-glycosyl hybrids 8 and 10 illustrated excellent broad inhibitory activity (IC50= 0.22 ± 0.01, 0.93 ± 0.42 and 0.24 ± 0.20 μM, respectively, for compound 8), (IC50 = 0.12 ± 0.50, 0.79 ± 0.14 and 0.15± 0. 60 μM, respectively, for compound 10), in comparison with the reference drugs, erlotinib, sorafenib and roscovitine (IC50 = 0.18 ± 0.05, 1.58 ± 0.11 and 0.46 ± 0.30 μM, respectively). In addition, the docking study was simulated to afford better rationalization and put insight into the binding affinity between the promising derivatives and their targeted enzymes and that might be used as an optimum lead for further modification in the anticancer field.

1 July 2018 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RBRasha Z. Batran
Rasha Z. Batran
AKAsmaa F. Kassem
Asmaa F. Kassem
EAEman M.H. Abbas
Eman M.H. Abbas
SESamia Elseginy
Samia Elseginy
MMMarwa M. Mounier
Marwa M. Mounier